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Purpose: Tissue factor pathway inhibitor (TFPI), an endogenous protease, is a potent 
inhibitor of the extrinsic pathway of coagulation. To determine whether TFPI could be 
used as an alternative to systemic heparin and dextran in vein bypass grafting procedures, 
we compared the efficacy of these agents in a blinded trial using a pig model of lower 
extremity vein bypass grafting. 
Methods: Yorkshire pigs (60 to 75 kg) were divided into four groups of five each: systemic 
heparin (5 ml 10 s U heparin, 50 ml intravenous dextran, and 10 U heparin/ml flush), 
local heparin (5 ml saline solution, 50 ml intravenous dextran, and 10 U heparin/ml 
flush), recombinant TFPI (rTFPI) (5 ml saline solution, 50 ml intravenous saline, and 
rTFPI 90 wg/ml flush), and control (5 ml and 50 ml intravenous saline and intravenous 
phosphate-buffered saline solution flush). The pigs were anesthetized and the lesser 
saphenous vein was harvested and reversed to construct a bypass from the common 
femoral artery to the saphenous artery at the hock. Each pig received two intravenous 
infusions before cross-clamping, and the artery and vein were flushed locally according to 
the protocol for each treatment group. Coagulation parameters were drawn 30 minutes 
after cross-damping. The surgical team was blinded as to the pigs' treatment group 
throughout the protocol. 
Results: The time from initial infusion until bypass completion averaged 80 minutes. 
Conduit patency rates at 7 days were as follows: four of five in the rTFPI group, three of 
five in the systemic heparin group, one of five in the local heparin group, and zero of five 
in the control group. The activated partial thromboplastin time was elevated (50.1 -+ 
13.8 seconds) with systemic heparin but not in the other groups. 
Conclusions: Local administration of TFPI prevents thrombosis as effectively as systemic 
heparin and dextran and is superior to local heparin flush plus dextran (p = 0.02). Thus 
local TFPI offers an excellent alternative to systemic heparin plus dextran and avoids the 
risks of systemic anticoaguiation. (J Vasc Surg 1997;25:726-9.) 
The extrinsic coagulation pathway begins with 
the association of  factor VI I  with the glycoprotein, 
tissue factor. Factor VI I  is converted to VIIa, and the 
tissue factor-factor Vi Ia complex in turn activates 
factor X and forms a tissue factor-v i Ia-Xa complex, 
which then activates factor IX and prothrombin. A
From the Surgical Service at the San Francisco Department of
Veterans Affairs Medical Center and the Division of Vascular 
Surgery, Department ofSurgery, University of California, San 
Francisco. 
Supported by the Northern California Institute for Research and 
Education and the Pacific Vascular Research Foundation. 
Reprint requests: Joseph H. Rapp, SFDVAMC (112), 4150 
Clement St., San Francisco, CA 94117. 
24/1/78146 
726 
specific inhibitor of this cascade, tissue factor path- 
way inhibitor (TFPI), binds to the tissue factor- 
VI Ia-Xa complex and renders it inactive. 1,2 The 
amino acid sequence of human TFPI has been deter- 
mined, 3and an active recombinant protein has been 
produced. TFPI  is a 43-kd glycoprotein with three 
Kunitz-type inhibitor domains. 4 It is normally found 
on circulating lipoproteins and endothelial cells and 
also has been called lipoprotein-associated coagula- 
tion inhibitor s,6 and extrinsic pathway inhibitor. 2
Recombinant TFPI  can effectively prevent intra- 
vascular thrombus formation 7,s and may be an effec- 
tive alternative to heparin in cardiovascular sur- 
gery. 9-11 Topical application o f rTFP I  has been used 
as an anticoagulant in experimental microvascular 
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Table I. Content of solutions A, B, and C in the experimental nd control groups 
rTFPI Systemic heparin Local heparin Control 
Solution A 5 ml 1V Saline solution Hepatin 103 U/ml  Saline solution Saline solution 
Solution B 50 ml IV Saline solution LMW dextran LMW dextran Saline solution 
Solution C local flush rTFPI 90 p~g/ml Heparin 10 U/ml Heparin 10 U/ml Buffer (PBS) 
IV, Intravenous; LMW, low molecular weight; PBS, phosphate-buffered saline solution. 
surgery, 9 where its use results in improved patency 
compared with heparin irrigation alone.a 0In trauma- 
tized canine arteries rTFPI prevented reocclusion 
after thrombolysis, 8 possibly because it has been 
found to remain bound at the site of arterial injury. 12 
Other data suggest hat perioperative use of rTFPI 
may have the added benefit of inhibiting neointimal 
hyperplasia after arterial trauma. ~1,13 
Thus rTFPI is a drug that could have important 
clinical utility. To examine whether rTFPI could 
replace systemic heparin in lower extremity vcin by- 
pass surgery, wc have cxamincd whcthcr local admin- 
istration of rTFPI is as effective an anticoagulant as 
systemic heparin and dextran in a porcine model of 
lower extremity bypass. 
METHODS 
Treatment groups 
Bcforc vein bypass surgcry, the pigs wcrc ran- 
domly assigned to one of four treatment groups: 
systemic hcparin (5 ml 103 U heparin, 50 ml intrave- 
nous dextran, and 10 U heparin/ml flush), local 
hcparin (5 ml saline solution, 50 ml intravenous 
dextran, and 10 U heparin/ml flush), rTFPI (5 ml 
saline solution, 50 ml intravenous saline, and rTFPI 
90 p~g/ml flush), and the control group (5 ml and 50 
ml intravenous saline solution and intravenous phos- 
phate-buffered saline solution flush (Table I). The 
appropriate solutions wcrc prcpared by a technician 
and were labeled. The surgical team was blinded as to 
the composition of these solutions until the entire 
experimental protocol was completcd. 
Because the research protocol was performed 
with the surgical team completely blinded as to 
which of the solutions was being used, the solutions 
were labeled A, B, and C. The solution used was 
determined by the random assignment of the pig to 
one of the trcatmcnt groups the night before the 
procedure. The appropriate selections of solutions A, 
B, and C were set out at the beginning of the proce- 
dure by a technician who was not a member of the 
surgical team. Each of  the solutions was colorless. 
Each pig was treated with only one systemic infusion 
of solution A and B, that is, each was given intrave- 
nously at the time of the initial cross-clamp. Local 
flushing of the vein and arteries with solution C was 
also per~brmed only once. The protocol did not 
allow the surgeons to give additional amounts of any 
of the solutions and extend the period of anticoagu- 
lation. Therefore, reclamping to perform a major 
revision of the vein graft was not possible. 
A total of six pigs were excluded from analysis 
before the unblinding of the study. Three pigs were 
excluded from the analysis as a result of technical 
problems that would have required extensive revi- 
sion. Two additional pigs were lost to analysis be- 
cause of  anesthetic omplications. One procedure 
was aborted because the solution C was spilled and 
could not be recovered. 
Procedure 
Female Yorkshire pigs (60 to 75 kg) were intu- 
bated and anesthetized using isoflurane. In securing 
the pig in a prone position the left lower extremity 
was not tied down, so that it could be extended to 
expose the cephalad surface of the limb and could be 
flexed to expose the caudad portion of the limb. 
With the limb extended, the groin was incised to 
expose the femoral artery at its bifurcation into the 
deep and superficial arteries. The soft tissue around 
the femoral artery was ligated to avoid seroma forma- 
tion. A second incision over the saphenous artery was 
made on the hock. A subcutaneous tunnel was cre- 
ated to connect hese two incisions. The limb was 
then flexed and extended cephalad, and an incision 
was made along the caudal surface to expose the 
lesser saphenous vein. The porcine vein is thin and 
elastic and can be easily twisted. To ensure that this 
would not occur it was marked in vivo every 2 to 3 
cm, and a silk suture was laid along the vein in vivo to 
ensure that it was not overextended when trans- 
planted as the arterial conduit. Approximately 5 ml 
of solution C was used to flush the harvested vein 
graft. 
After vein harvest and immediately before clamp- 
ing the t~moral artery each pig was given 5 ml of 
solution A and 50 ml of  solution B by intravenous 
bolus injection. On clamping and creating the arteri- 
otomy, the artery was flushed proximally and distally 
through the open vessel with approximately 1 ml of 
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Table II. Vein graft patency at 1 and 7 days 
rTFPI Systemic heparin Local heparin Control 
1 day 5/5" 3/5 1/5 0/5 
7 days 4/5" 3/5 1/5 0/5 
*p < 0.02 versus local heparin group. 
solution C. The open vessel was also flushed. The 
vein was reversed and an anastomosis created using 
6-0 polypropylene suture. After the femoral anasto- 
mosis was completed, the vein was placed through 
the subcutaneous tunnel. The saphenous artery was 
ligated proximally and clamped distally. After the 
arteriotomy was made, approximately 0.5 ml of solu- 
tion C was flushed istally and in the open arteriot- 
omy. This distal anastomosis was completed using 
7-0 polypropylene suture. The vein grafts varied in 
length from 14 to 17 cm. The time from infusion of 
solutions A and B until both anastomoses were com- 
pleted ranged from 67 to 84 minutes. Blood was 
withdrawn from an ear vein before administering the 
systemic infusions and 30 minutes after they were 
given. 
Patency was established 1 day after surgery either 
by palpation or by Doppler examination. If the pig 
was uncooperative, ketamine anesthesia was given to 
allow inspection of the operative site. If the grafts 
were occluded, they were harvested as noted below. 
On the seventh day after surgery the pigs were anes- 
thetized. The grafts were examined for patency, and 
the wounds over the femoral and saphenous arteries 
were opened and the anastomotic sites removed 
along with 1 to 2 cm of proximal and distal artery 
and vein. 
All procedures were performed with the approval of 
the Animal Studies Committee of the San Francisco 
Veterans Affairs Medical Center. Each pig was given 1 
gm of chloramphenicol atthe beginning of the proce- 
dure and 106 units ofpeniciUin daily after surgery. 
RESULTS 
Graft patency. Graft patency at 1 and 7 days is 
shown in Table II. All grafts were occluded within 24 
hours when the bypass was constructed without an- 
ticoagulation. Only one graft remained patent 
among the pigs treated with local heparin flush and 
systemic dextran. When pigs were treated with either 
systemic heparin or local rTFPI, graft patency was 
improved compared with those treated with local 
heparin and systemic dextran (p < 0.02). 
Systemic anticoagulation. The prothrombin 
time was not elevated in any group. The activated 
partial thromboplastin time was elevated only in the 
systemic heparin group at 50.1 + 13.8 seconds. 
DISCUSSION 
The routine use of heparin to achieve systemic 
anticoagulation is one of the key factors that ushered 
in the modern era of cardiovascular surgery, laHepa- 
rin has an immediate onset of action, a relatively 
short half-life, and is easily reversible. To date, the 
only alternative to heparin has been anticoagulation 
therapy with warfarin, which requires everal days of 
oral therapy before surgery, and if reversal is neces- 
sary the patient must undergo infusion of fresh fro- 
zcn human plasma. In this experimental study we 
have shown that the local infusion ofrTFPI can be a 
satisfactory substitute for heparin in a porcine model 
of lower extremity bypass without creating systemic 
anticoagulation. 
There are several theoretic advantages to using 
this effective local anticoagulant during vascular pro- 
cedures. The obvious indication for rTFPI would be 
in patients who have developed heparin-associated 
thrombocytopenia. There may also be a rare patient 
in whom extremity revascularization s indicated but 
in whom systemic anticoagulation poses a particu- 
larly high risk, for example, immediately after a neu- 
rologic procedure. The routine use of a local antico- 
agulant could reduce the incidence of wound 
hematomas and would likely limit blood loss. It 
could also reduce the risk of bleeding during proce- 
dures that are routinely used to prepare the patient 
for surgery, such as epidural and central vein cannu- 
lation. 
However, there also could be potential disadvan- 
tages of local anticoagulation. Systemic anticoagula- 
tion may reduce the incidence of postoperative d ep 
venous thrombosis seen after vascular surgical proce- 
dures. 
This experimental protocol was developed to de- 
termine whether rTFPI could be administered locally 
and achieve adequate anticoagulation for a vein by- 
pass grafting procedure. Repeated flushing of the 
rTFPI solution could result in levels that would cre- 
ate systemic anticoagulation. Because each proce- 
dure was performed with the entire operating team 
blinded as to the content of solutions A, B, and C, 
the degree of systemic anticoagulation achieved was 
not monitored and the pigs were not given addi- 
tional doses of solutions A or B. Therefore, in this 
protocol each vessel was flushed only at the time of 
the arteriotomy, and the systemic nfusions were lim- 
ited to only a single administration. Retreatment 
systemically with solution A or B or repeated local 
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flushing with solut ion C may have reduced the num- 
ber o f  graft occlusions in all groups. Of  the grafts that 
failed, all except one failed within the first 24 hours, 
presumably because o f  early thrombus formation. 
One graft treated with rTFP I  failed between 24 
hours and 7 days. This most likely represents a tech- 
nical problem with the graft and not  a tendency for 
rTFP I  treated grafts to occlude in the late postoper-  
ative period. 
A 24-hour  infusion o f  TFP I  has been shown to 
prevent restenosis in a hyperl ipemic minipig model  
o f  angioplasty injury. 13 Infusions o f  TFP I  and other 
specific inhibitors o f  the early initiators o f  the extrin- 
sic coagulat ion pathway have also reduced neointi-  
mal hyperplasia fter arterial injury in rabbits. 1~ Thus 
using local rTFP I  in vascular procedures could afford 
some protect ion from the later development o f  inti- 
mal hyperplasia, a l though conformat ion that these 
observations apply to the human clinical situation 
will be needed. 
CONCLUSION 
Local infusion with rTFPI  appears to offer an excel- 
lent alternative to systemic anticoagulation with hepa- 
rin in a porcine model  of  lower extremity vein bypass. I f  
clinical trials demonstrate that local anticoagulation 
with rTFPI  can be effective in human vascular bypass 
procedures, it will allow bypass procedures to be per- 
formed in patients who have hepafin-induced throm- 
bocytopenia or those in whom systemic anticoagula- 
tion would be contraindicated. In addition, the 
antiinflammatory characteristics of this novel molecule 
may limit postoperative infimal hyperplasia and make it 
an attractive alternative to heparin. 
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